Are weight-loss pills about to become reality?
Novo Nordisk Acquires Septerna: A Strategic Move Toward Oral Obesity Medications At a time when the fight against obesity and metabolic diseases is intensifying, Novo Nordisk has made a major move by acquiring the biotechnology company Septerna. The deal, valued at up to $2.2 billion, marks a strategic expansion of Novo Nordisk’s portfolio into innovative oral therapies, with a strong
Read more